68Ga-PSMA-11 PET/CT代谢参数用于确定前列腺癌全身肿瘤负荷及治疗反应
本研究纳入142例生化复发前列腺癌患者,行68Ga-PSMA-11 PET/CT定量评估全部641个阳性病灶,计算PSMA-TV、TL-PSMA、SUVmax和SUVmean,并与血清PSA及Gleason评分关联。23例治疗前后复查者中,TL-PSMA与生化反应一致率87%,高于SUVmax的74%,且均高于CT基于RECIST 1.1的评估。
要点
- PSMA-TV和TL-PSMA与血清PSA水平显著相关(P<0.0001)。
- TL-PSMA在不同Gleason评分间有显著差异。
- TL-PSMA与生化反应一致率87%,高于SUVmax的74%。
核心结论
- 68Ga-PSMA-11 PET/CT衍生的代谢肿瘤参数在评估治疗反应方面显示出有前景的结果,尤其是TL-PSMA与生化反应的一致率高于SUVmax。
- 作者认为需要更大规模、理想情况下为前瞻性的试验来帮助揭示68Ga-PSMA-11 PET代谢参数的完整潜力。
研究设计与样本
- 共纳入142例生化复发前列腺癌患者,行[68Ga]Ga-PSMA-HBED-CC(68Ga-PSMA-11)PET/CT检查。
- 对视野内全部641个68Ga-PSMA-11阳性病灶进行定量评估,计算全身PSMA肿瘤体积(PSMA-TV)、全身总病灶PSMA(TL-PSMA)以及SUVmax和SUVmean。
- 所有PET衍生参数均检验与血清PSA水平的相关性及与Gleason评分的关联。
- 23例患者在体外 beam 放疗、雄激素剥夺或 docetaxel 化疗前后行68Ga-PSMA-11 PET/CT,比较SUVmax和TL-PSMA与基于RECIST 1.1标准的CT影像学反应评估及血清PSA变化确定的生化反应。
主要发现
- PSMA-TV和TL-PSMA与血清PSA水平呈显著相关(P < 0.0001)。
- TL-PSMA在不同Gleason评分间有显著差异。
- TL-PSMA与生化反应的一致率为87%(95%CI 0.66-0.97;Cohen's κ = 0.78;P < 0.01),高于SUVmax的74%(95%CI 0.52-0.90;κ = 0.55;P < 0.01)。
- TL-PSMA和SUVmax与PSA的一致率均高于基于CT的反应评估。
- PET与CT的不一致结果最可能归因于CT和RECIST在评估小淋巴结为转移及骨受累方面的局限性,后者有时在CT上不可检测。
关键数值与推荐
- TL-PSMA与生化反应一致率87%(95%CI 0.66-0.97;Cohen's κ = 0.78;P < 0.01)。
- SUVmax与生化反应一致率74%(95%CI 0.52-0.90;κ = 0.55;P < 0.01)。
- PSMA-TV和TL-PSMA与血清PSA水平相关(P < 0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- PET与CT的不一致结果最可能归因于CT和RECIST在评估小淋巴结为转移及骨受累方面的局限性,后者有时在CT上不可检测。
- 作者认为需要更大规模、理想情况下为前瞻性的试验来帮助揭示68Ga-PSMA-11 PET代谢参数的完整潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We aimed at evaluating the role of 68Ga-PSMA-11 PET/CT-derived metabolic parameters for assessment of whole-body tumor burden and its capability to determine therapeutic response in patients with prostate cancer. METHODS: A total of 142 patients with biochemical recurrence of prostate cancer underwent PET/CT with [68Ga]Ga-PSMA-HBED-CC (68Ga-PSMA-11). Quantitative assessment of all 641 68Ga-PSMA-11-positive lesions in the field of view was performed to calculate PSMA-derived parameters, including whole-body PSMA tumor volume (PSMA-TV) and whole-body total lesion PSMA (TL-PSMA), as well as the established SUVmax and SUVmean values. All PET-derived parameters were tested for correlation with serum PSA levels and for association with Gleason scores. In 23 patients who underwent 68Ga-PSMA-11 PET/CT before and after therapy with either external beam radiation, androgen deprivation, or docetaxel chemotherapy, SUVmax and TL-PSMA were compared to radiographic response assessment of CT images based on RECIST 1.1 criteria and to biochemical response determined by changes of serum PSA levels. RESULTS: PSMA-TV and TL-PSMA demonstrated a significant correlation with serum PSA levels (P < 0.0001) and TL-PSMA was significantly different for different Gleason scores. The agreement rate between TL-PSMA derived from PET and biochemical response was 87% (95% confidence interval, 0.66-0.97; Cohen's κ = 0.78; P < 0.01) and, thus, higher than for SUVmax, which was 74% (95% CI, 0.52-0.90; κ = 0.55; P < 0.01). Furthermore, agreement with PSA was higher for TL-PSMA and SUVmax than for CT-based response evaluation. Discordant findings between PET and CT were most likely due to limitations of CT and RECIST in rating small lymph nodes as metastases, as well as bone involvement, which was sometimes not detectable in CT. CONCLUSION: 68Ga-PSMA-11 PET/CT-derived metabolic tumor parameters showed promising results for evaluation of treatment response. Especially, TL-PSMA demonstrated higher agreement rates with biochemical response compared to SUVmax. Larger, ideally prospective trials are needed to help to reveal the full potential of metabolic parameters derived from PET imaging with 68Ga-PSMA-11.
引用
- Schmidkonz C, Cordes M, Schmidt D, et al. 68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. Eur J Nucl Med Mol Imaging. 2018. PMID: 29725716. doi:10.1007/s00259-018-4042-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。